FibroGen Inc
FGEN
ISIN US31572Q8087 / Valor 25953994
FibroGen Inc
UMushroom community rating:
About company
FibroGen Inc is a biopharmaceutical company focused on developing innovative therapies for various medical conditions. One of their potential first-in-class products is FG-3246, an antibody-drug conjugate being developed for metastatic castration-resistant prostate cancer and other tumor types. Another promising drug in their pipeline is Pamrevlumab, a human monoclonal antibody designed to inhibit the activity of connective tissue growth factor in proliferative disorders and certain cancer cell types. Additionally, FibroGen is working on Roxadustat, an oral small molecule inhibitor for treating chemotherapy-induced anemia. These investigational drugs are at various stages of clinical development and have the potential to address significant unmet medical needs in the market.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
1566 M
Market cap (USD)
58,256
Daily traded volume (Shares)
0.4852 / 0.4522
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
